#
Feb 17, 2024
An update on the MOVE FSHD study.
#
Feb 17, 2024
Dr. Heher's final report on very interesting data regarding oxidative stress.
#
Feb 1, 2024
Dr. Chamberlain is honored by the MDA with the 2024 Legacy Award for Achievement in Research.
#
Jan 30, 2024
Dr. Arends provides an update to current work.
#
Oct 10, 2023
Latest update from the MOVE grant.
#
Sep 19, 2023
We have developed a computational cellular model of FSHD, based on a mechanism where expression of DUX4 (currently the main target for FSHD therapy) leads to muscle cell death.
#
Jul 5, 2023
Initial progress update.
#
Jul 5, 2023
Friends of FSH Research continues support of local artists, who in turn have donated much to the annual Auction. Live music returns to the Wedgwood Art Festival this year! Two headlining bands and a great lineup of local musicians in the Hellbent Brewery beer garden.
#
Apr 6, 2023
Final update by Dr. Ozes of Altay Therapeutics.
#
Mar 23, 2023
FlexFund grant on support for continued development of low-cost FSHD diagnostic test.
#
Feb 5, 2023
This large study will be a big achievement in the FSHD community, a reality that has been made possible by the support from Friends of FSH Research.
#
Dec 17, 2022
New Publication from Grant Recipient: Professor Zammit at King's College
#
Nov 14, 2022
Here's YOUR chance to attend a Seahawks game and support FSHD research at the same time!
#
Oct 31, 2022
A thank you letter from Dr. Bloch.
#
Oct 28, 2022
Final report of year one.
#
Oct 16, 2022
Friends of FSH Research is calling for grant proposals now for final submission by the end of January 2023 with funding in March 2023.
#
Oct 11, 2022
Final update by Dr. Bosnakovski.
#
Oct 4, 2022
The mission of Friends of FSH Research is to accelerate research that will help find a treatment or cure for FSH muscular dystrophy. This strategy sometimes requires us to fund unique, novel and potentially risky research pilot projects.
#
Aug 23, 2022
FSHD Clinical Trial Research Network Quarterly Newsletter - Summer 2022
#
Aug 23, 2022
CMS has accepted a formal request to consider both the benefit category and coverage for seat elevation systems and standing systems.